Clinical Trials · NCT06607666
Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Enrollment
- 102
- Start date
- Jan 2023
- Locations
- 1 site, Italy
- Primary endpoint
- Lanreotide ATG efficacy